BioNTech (BNTX) announced that Ryan Richardson will step down as Chief Strategy Officer in the Management Board of BioNTech on September 30, and as a Board Director at affiliated companies of the BioNTech Group by mutual agreement to pursue new professional opportunities. The process of transitioning his responsibilities to other members of the Management Board is underway, ensuring a smooth handover. Ryan Richardson joined BioNTech in 2018 and has served as CSO since January 2020.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech price target lowered to $126 from $127 at BofA
- BioNTech’s Promising Phase III Trial for Recurrent Endometrial Cancer
- BioNTech’s Latest Clinical Trial: A New Hope for Lung Cancer Treatment?
- BioNTech’s Phase II Trial: A Potential Game-Changer in Colorectal Cancer Treatment
- BioNTech’s Promising Trial: BNT113 and Pembrolizumab in Head and Neck Cancer